Articles from STEMCELL Technologies

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.

STEMCELL Technologies has commercially launched the CellPore™ Transfection System, providing a groundbreaking new technology with the potential to advance cell engineering research and the development of novel cell therapies to cure diseases.

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.

STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation).

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Propagenix Inc.—a Maryland-based biotechnology company focused on developing technologies to enable new approaches in regenerative medicine.

STEMCELL Technologies, Canada’s largest biotechnology company, has received the Canada's Most Admired Corporate Cultures™ of 2023 award by Waterstone Human Capital. This national awards program recognizes best-in-class Canadian organizations for fostering high-performance corporate cultures that help sustain a competitive advantage.

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the opening of its new Canadian sales office at the MaRS Centre in downtown Toronto, Ontario.

STEMCELL Technologies, Canada’s largest biotechnology company, is releasing its first annual sustainability report today. The report, entitled Toward Sustainable Science, provides a comprehensive look at STEMCELL’s environmental, social, and governance performance over the company’s 2023 Fiscal Year (July 1, 2022 through June 30, 2023).

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver.

STEMCELL Technologies, Canada’s largest biotechnology company, is marking its 30th year of accelerating research into cancer and other diseases by celebrating its culture of collaboration, curiosity, and discovery.

STEMCELL Technologies is proud to announce its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honourable Mary Simon, the Governor General of Canada.

STEMCELL Technologies, Canada’s largest biotechnology company, announced today that it has received ISO 14001:2015 certification of its Environmental Management System at its Canadian operations in Vancouver, BC.

STEMCELL Technologies announces the launch of human pluripotent stem cell (hPSC) characterization and banking services in partnership with WiCell®. These services, offered through STEMCELL’s Contract Assay Services division, will provide researchers with comprehensive cell quality assessments and enable them to generate cell banks using standardized practices. Ultimately, this will reduce variability and improve reproducibility for various downstream applications, including disease modeling, drug discovery, toxicology screening, and regenerative medicine research.

STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help researchers and organizations working on drug development incorporate organoids into their preclinical testing programs and bring new therapeutics to market faster and more cost-effectively.